New radiopharma Actithera emerges with $75.5m in financing
A new player in radioligand therapies, Actithera, has arrived on the scene with $75.5m in funding and lead FAP-targeted candidate for cancer.
From trauma to healing: How therapy complements medication i...
Trauma therapy is more than just talk – it’s an evidence-backed process that helps patients reframe, process, and recover from life-altering events.
Tech for good: AI agents critical to improving NHS services
How NHS Trusts are harnessing the latest AI solutions to optimise the experience for their employees and care on behalf of patients.
Taiho's late-stage Duchenne candidate fails trial
Taiho has suffered a blow to its near-term pipeline after a drug candidate for Duchenne muscular dystrophy (DMD) missed the mark in a phase 3 trial.
Featured Content
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content
The World's Definitive Degrader & Proximity-Based Drugs Even...
The 8th Annual TPD & Induced Proximity Summit is the world’s largest and longest-standing forum for proximity-based modalities
Welcome to the 7th Exosome-Based Therapeutic Development Sum...
Accelerate Therapeutic Efficacy & Delivery Potential of Exosomes & EVs
Welcome to the 10th CDD for Biologics Summit
Accelerate Therapeutic Efficacy & Delivery Potential of Exosomes & EVs
The Inaugural Multi-Omics Based Drug Discovery & Development
The Industry-Led Forum Dedicated to Expanding the Applications of Multi-Omics Across Therapeutic Development
2nd Translational Digital Pathology & AI Summit
Don’t miss the return of this event, uniting 60+ leading biopharma pioneers driving the adoption and utilization of digital pathology